US President Joe Biden on Tuesday announced a collaboration between Johnson & Johnson, Merck, and the federal government to ramp up COVID-19 vaccine production.This comes days after the Food and Drugs Administration (FDA) announced that it had approved the Janssen COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older.Delivering his remarks at the White House, Biden announced the partnership: "Two of the largest health care and pharmaceutical companies in the world that are usually competitors are working together on the vaccine.""This type of collaborations between the countries we have seen in World War II. We have also invoked the defence production act to equip Merck facilities to safely manufacture the J & J vaccine," he addedBiden said that because of a stepped-up production process, the United States will have enough novel coronavirus vaccines for every American adult by the end of May."This country will have enough vaccines supply for ..
President Joe Biden is expected to make the announcement on Tuesday, the report said
The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday
Frazier, 66, will remain with the drugmaker as executive chairman for a transition period to be determined by the board.
That is above the average of 404 drug price increases in the first three days of January over the past five years
The spread in the yield curve has gainedabout 20 basis points since leaving negative territory, a recession indicator, in early September
Out of the 77.80% paid-up equity share capital, 51.80% was held by current promoters and up to 26% by public shareholders: Merck
The stock locked in the lower circuit for the second straight day, down 5% at Rs 3,064 on the BSE.
Thus far in the calendar year 2018, the stock of this pharmaceutical company has zoomed 107% from Rs 1,289, as compared to 4% rise in the S&P BSE Sensex.
The stock hit new high of Rs 2,369, rallied 57% from Rs 1,510 since April 19, after P&G Overseas India makes mandatory open offer to acquire 26% stake in the company at price of Rs 1,500.36 per share.
The stock surged 19% to Rs 1,795, also its record high on the BSE after the Procter & Gamble Overseas India makes mandatory open offer at price of Rs 1,500.36 per share
The life science division which manufactures laboratory materials, chemicals and is the largest of its segment in India
is exploring sale or strategic partnership for its consumer health business including India as it continues focus to develop innovative drugs.The plan to hive off consumer health business is second such move by the drug maker which sold its biosimilar business to Fresenius earlier this year.The German drug maker Merck KGaA operates in 66 countries and its business is spread across pharmaceuticals, laboratory solutions, chemicals and liquid crystals. In 2016 the company had global sales of over 15 billion Euros. Consumer health contributed to 850 million Euros.Merck, which has been present in India for over five decades, operates through five main companies including its listed entity Merck Limited. Merck did not respond to an email query and did not share the most recent consumer health sales figures for India. Merck Ltd 2015 annual report shows the business contributed over Rs 200 crore or around 24 per cent of its Rs 904 crore sales (the company follows January-December ...
Lab will also help with technology absorption, making drugs for clinical trials and regulatory nods
The stock rallied 13% to Rs 906 in intra-day after reported profit of Rs 27.54 crore in Q3CY16 against Rs 12.51 crore in the same quarter last year.